$57.95 1.58 (+2.80%)
11/9/2009 10:09 AM

Alexandria Real Estate Equities, Inc. (ARE)

CAPS Rating: 1 out of 5

The Company is engaged principally in the ownership, operation, management, selective redevelopment, development and acquisition of properties for the life sciences industry.

Current Price $57.95 Mkt Cap $2.28B
Open $56.81 P/E Ratio 18.13
Prev. Close $56.37 Div. (Yield) 1.40 (2.50%)
Daily Range $56.79 - $58.11 Volume 86,321
52-Wk Range $30.33 - $67.50 Avg. Daily Vol. 790,000

ARE News and Commentary

Caps

How do you think ARE will perform vs the S&P 500?

Add Stock to Watchlist

All Members

76 Outperform
50 Underperform
 

All-Star Members

20 Outperform
19 Underperform
 

Wall Street

8 Outperform
1 Underperform
 

Top ARE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

SuperCharge (98.18)
Submitted July 13, 2009

The "leading provider of real estate..., (and) landlord of Choice to the Life Science Industry".

Debt's a little high but improving & ARE's near the 52 week lows. If you're like me & expect the life science's to hold up… More

2 Comments | Reply | Report this Post

Ewok82 (30.52)
Submitted May 25, 2009

Expensive property in a niche market for life science research seems to be a bit speculative in this market, especially given that some of these properties are in cities like SF, where prices continue to fall as taxes continue to rise.

0 Comments | Reply | Report this Post
ARE VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about ARE.

Recs

0
Member Avatar Sicheng (87.14) Submitted: 8/16/2009 4:57:12 AM : Outperform Start Price: $47.76 ARE Score: +10.07

ARE price unfortunately went down too much. It has specialty in building labs for life scicence companies. Recent quarters shows it's strength over other commercial REITs, they are no worse than even in 2008, but price is in 60% discount now. Plus, last month it just got a long-term leasing contract in NYC from Eli Lilly. People will realize that it's still undervalued in the next 2 - 4 quarters. I bought a little in early July and more last week.

Report this Post 0 Comments | Reply | Permalink

Recs

1
Member Avatar SuperCharge (98.18) Submitted: 7/13/2009 2:16:59 PM : Outperform Start Price: $31.65 ARE Score: +60.05

The "leading provider of real estate..., (and) landlord of Choice to the Life Science Industry".

Debt's a little high but improving & ARE's near the 52 week lows. If you're like me & expect the life science's to hold up ok in this downturn, ARE looks like a pretty good bargain here. Could go lower, but the cut dividend is still yielding 4+% and earnings have shown stregth of late.

The 5 year avg. P/E is 36 and ARE's sitting at about 8 right now. Watch the 2Q earnings report closely. I don't expect it to, but if the 2nd Q's near MSN's projected $1.37 there's no reason why this thing shouldn't skyrocket. That $1.37 figure has to be a mistake because their 2009 guidance is suggesting $2.5 per share. Even still, that puts ARE at reasonable FWD P/E of 12.

Report this Post 2 Comments | Reply | Permalink

Recs

1
Member Avatar Ewok82 (30.52) Submitted: 5/25/2009 12:49:11 PM : Underperform Start Price: $31.59 ARE Score: -57.90

Expensive property in a niche market for life science research seems to be a bit speculative in this market, especially given that some of these properties are in cities like SF, where prices continue to fall as taxes continue to rise.

Report this Post 0 Comments | Reply | Permalink
View All 24 Pitches »

Leaderboard

Find the members with the highest scoring picks in ARE.

Score Leader

mikotian

mikotian (99.91) Score: +79.16

The Score Leader is the member with the highest score across all their picks in ARE.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
SSPX3 < 20 5/14/2009 Outperform NS $30.50 +88.53% +23.61% +64.92
JRWare 97.71 7/13/2009 Outperform 3Y $31.02 +85.34% +23.50% +61.85
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. SuperCharge 98.18 7/13/2009 Outperform NS $31.65 +81.68% +21.62% +60.05 3 Comments
Eudemonic < 20 7/15/2009 Outperform 5Y $32.83 +75.13% +18.78% +56.35
czarl 69.83 5/27/2009 Outperform NS $34.77 +65.38% +19.94% +45.43
TraderJFH 93.57 7/22/2009 Outperform 1Y $36.61 +57.06% +13.92% +43.14
zackmax 93.35 9/30/2008 Underperform 5Y $103.77 -44.59% -1.90% +42.69 1 Comment
crabbucket1 32.88 5/4/2009 Outperform 3M $34.75 +65.47% +23.86% +41.62 1 Comment
mitchiemono 67.52 4/27/2009 Outperform 1Y $35.57 +61.67% +28.01% +33.66
NSHanlon 48.78 4/27/2009 Outperform 3Y $35.57 +61.67% +28.01% +33.66
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackRWBaird 84.59 9/1/2009 Outperform NS $55.51 +3.59% +6.54% -2.95
TrackJMP < 20 8/4/2009 Outperform NS $39.34 +46.16% +9.07% +37.09
TrackUBS 86.20 9/17/2008 Outperform NS $101.18 -43.17% -6.43% -36.74
TrackChrisDavis < 20 6/3/2008 Outperform 1Y $96.12 -40.18% -19.20% -20.98 1 Comment
TrackRonBaron 23.63 3/31/2008 Outperform NS $86.60 -33.60% -14.71% -18.89 1 Comment
TrackHeebner 32.36 12/31/2007 Outperform NS $94.16 -38.93% -22.63% -16.30 3 Comments
TrackCantorFitz 40.20 1/31/2007 Outperform NS $95.93 -39.59% -19.26% -20.33
TrackRBCCapMkts 81.53 11/7/2006 Underperform NS $86.34 -32.88% -16.68% +16.20
TrackRyanBeck 60.31 10/26/2006 Outperform NS $88.40 -34.45% -16.97% -17.47

Featured Broker Partners